Background
==========

Most randomised trials are produced in the USA. Certainly, when it comes to trials relevant to the care of people with schizophrenia, certain countries have a strong tradition of trialling, and others have not \[[@B1]\]. This study investigates whether certain accessible economic and/or demographic variables are, in some way linked, and can be predictive of productivity of schizophrenia trials.

Methods
=======

The Cochrane Schizophrenia Group has constructed a unique collection of reports of randomised controlled trials relevant to schizophrenia \[[@B2]\]. In this collection a single electronic record is made per study and the multiple references/reports/presentations of that study are appended to that single record. This attempt to decrease the confusion caused by \'salami\' publication is made possible using custom made specialised reference/study management software \[[@B3]\]. A study-based register affords an opportunity for research. Each study record in the Cochrane Schizophrenia Group\'s database has been coded for \'country of origin\'. This has had to be defined as the country from which the first author originates. These data were extracted from the database (currently 5062 studies), and the number of trials undertaken in each country calculated.

Data for gross domestic product (GDP), population, GDP/Capita, and the number of telephones/100 people, for all countries, were acquired from the United Nations website \[[@B4]\]. A second website was used to supplement the first dataset where gaps were apparent \[[@B5]\]. Both datasets were figures from 1997. These particular sets of data were chosen as they are widely accessible, and because the authors felt they each add some qualities worthy of consideration. GDP is a measure of the sheer wealth of a nation. The population is the number of people, and, with a lifetime prevalence of 1% for schizophrenia, it represents the numbers of people with the illness who live in the country. GDP/capita is a measure of potential individual affluence, and number of telephones/100 people, is a crude estimate of technical development.

Statistical analysis was performed using StatsDirect, Statistical Software \[[@B6]\]. Number of randomised controlled trials relevant to schizophrenia was correlated against each of the four economic/demographic variables using simple and linear regression and Pearson\'s correlation calculated (Appendix 1 \[see [Additional file 1](#S1){ref-type="supplementary-material"}\]). Finally, the best-fit plot was used to interpolate X (economic/demographic variable of best fit) to Y (calculated number of trials). In this way it was hoped to estimate the expected output of schizophrenia trials and compare this to the actual output.

Results
=======

Of the 5062 studies, 61 (1.21%) were reported in such a way as to make reliable data extraction of country of origin impossible. Data extraction for \'country of origin\' defined in the way used in this study has been found to be reliable in this sample with over 90% agreement \[[@B6]\]. Simple frequencies of studies by country verify that the USA is the most productive country of schizophrenia trials (Table [1](#T1){ref-type="table"}).

###### 

Top 10 producers of schizophrenia trials

  **Country**      **Simple frequency of trials (n)**
  ---------------- ------------------------------------
  USA              2363
  United Kingdom   669
  Canada           275
  Germany          256
  Japan            113
  France           108
  Netherlands      104
  Sweden           101
  Italy            91
  China            87
  TOTAL            4167

Correlation of the number of trials by each of the four variables is shown in Table [2](#T2){ref-type="table"}.

###### 

Correlation of number of trials (if \>0) vs each variable

  **Variable**                     **r**   **95% CI for r**   **r^2^**
  -------------------------------- ------- ------------------ ----------
  GDP (in million US \$)           0.87    0.79 to 0.92       0.76
  Population (in thousands)        0.14    -0.11 to 0.38      0.02
  GDP/Capita (US \$)               0.31    0.06 to 0.52       0.10
  Telephones/per 100 inhabitants   0.30    0.06 to 0.52       0.09

The correlation with GDP was by far the best fit with 76% of the total variation about the Y explained by the regression line (log transformation made little difference to the analysis). Having created the best-fit line, GDP data from every country, whether or not they had been found to produce a relevant randomised trial, were interpolated to estimate the number of trials predicted by GDP.

The results of these interpolations fell into three distinct groups: i. Countries for which we had failed to identify any schizophrenia randomised trials; ii. Countries which had produced schizophrenia trials and which had a GDP that predicted trial activity; and finally, iii. Countries for which the GDPs predicted no trial activity, but that had undertaken a number of relevant studies.

Countries with no schizophrenia trials
--------------------------------------

We could not identify any randomised controlled trial research for people with schizophrenia for 132 (out of 192) countries. All of these countries, with the exception of Indonesia and Iraq had such low GDPs that trial activity would not be expected. Indonesia\'s GDP of \$214593 million/year suggests that 25 studies could be expected, but wide confidence intervals do not exclude zero productivity (95% CI -16 to 66). The same applied for Iraq\'s \$149036 million/year, with nine trials predicted but similarly wide confidence intervals (95% CI -32 to 51).

Countries productive of schizophrenia trials and also with a GDP that predicted trial activity (Table [3](#T3){ref-type="table"})
---------------------------------------------------------------------------------------------------------------------------------

###### 

Countries productive of schizophrenia trials ordered by level of productivity

  **country**          **GDP (mUS \$)**   **actual trials \> 100**   **predicted trials**   **% predicted output (95% confidence intervals)**
  -------------------- ------------------ -------------------------- ---------------------- ---------------------------------------------------
  Finland              119834             38                         2                      1900 (1312--2488)
  South Africa         129094             26                         5                      520 (340--700)
  Denmark              161455             79                         12                     658 (525--792)
  Canada               607702             275                        118                    233 (212--254)
  Norway               153362             24                         10                     240 (167--313)
  Greece               118172             15                         2                      750 (397--1103)
  Switzerland          172400             54                         15                     360 (278--442)
  Sweden               227757             101                        28                     361 (301--421)
  Poland               135623             17                         6                      283 (175--392)
  UK                   1283335            669                        279                    240(226--254)
  Netherlands          363342             104                        60                     173(152--196)
  Belgium              242508             49                         32                     153 (128--178)
  Austria              206236             33                         23                     143 (117--170)
  USA                  7824008            2363                       1831                   129 (127--132)
  Hong Kong            175200             18                         16                     113 (95--130)
  Australia            402787             64                         70                     91 (85--98)
  India                388649             48                         66                     73 (60--85)
  Germany              2089845            256                        470                    54 (48--61)
  Nigeria              142920             4                          8                      50 (1--99)
  China                901981             87                         188                    46 (36--57)
  Turkey               191865             8                          19                     42 (8--76)
  Thailand             153909             4                          10                     40 (-8--88)
  Italy                1145370            91                         246                    37 (27--47
  France               1394124            108                        305                    35 (26--44)
  Spain                531289             32                         100                    32 (16--48)
  Russian Federation   447103             21                         80                     26 (7--45)
  Mexico               402109             13                         69                     19 (-2--40)
  Iran                 159391             2                          12                     17 (-35--68)
  Saudi Arabia         134825             1                          6                      17 (-56--90)
  Republic of Korea    442543             13                         79                     16 (-4--37)
  Brazil               806972             21                         166                    13 (-2--27)
  Argentina            323548             6                          51                     12 (-14--38)
  Japan                4192669            113                        969                    12 (6--18)
  Taiwan               308000             4                          47                     9 (-19--36)

Finland is far ahead of other nations but numbers of both actual and expected studies are small. Denmark, however, is highly productive, as is Sweden, the UK, Canada and the Netherlands. Using these data, the USA\'s strong tradition of undertaking and disseminating trials still is outstanding, but it is the 14^th^most productive country of schizophrenia trials, according to percent of predicted output.

Countries for which GDP predicted no trial activity, but which had undertaken relevant studies
----------------------------------------------------------------------------------------------

Twenty-five countries fell into this category, five of which produced more than ten studies when none were predicted by GDP (Table [4](#T4){ref-type="table"}).

###### 

Countries with GDPs that predicted no studies, but with \>10 trials

  **Country**                      **GDP (million US \$)**   **Trials**
  -------------------------------- ------------------------- ------------
  Israel                           92587                     83
  Czech Republic                   52038                     78
  New Zealand                      65291                     14
  Yugoslavia (Serbia/Montenegro)   17000                     10
  Hungary                          45725                     10

Discussion
==========

Strengths and limitations
-------------------------

There are several limitations of the datasets used for this work. The study-based register is in its first draft. Many papers may be designated as a unique study when they only represent another report of an already identified randomised trial. Being fully confident of having minimised undisclosed multiple publications would take some time. This limitation will result in an overestimate of the number of studies. The overestimate probably is greatest for English language reports of industry-sponsored trials, the great majority of which originate from the USA. A second limitation is that the studies are from 1950 to the present day but the economic/demographic data are from 1997, disregarding the economic/demographic/political changes over time.

Economies that developed rapidly after World War II, such as China, Germany, Italy, Japan, Korea and Taiwan are being judged by the GDP of 1997. This technique could overestimate the expected output of trials from countries in which average GDP, or GDP relative to other countries, would have been considerably less than that of 1997. The crude definition of country of origin as country from which the first author originates is also a limitation. The author\'s origin may not represent the country where the study took place and we do not know the proportion of studies for which this accurately reflects where the work was undertaken. Lastly, the use of GDP is potentially a surrogate measure of one or many causal relationships. It could be a surrogate for the national investment of the pharmaceutical industry, the funding and activity of universities, or/and the degree to which fragmentation of the family had lead to public concern about the care of people with schizophrenia. As with any correlation study, this work is solely hypothesis-generating and not testing.

The USA produces more schizophrenia trials than any other country (Table [1](#T1){ref-type="table"}). When the correlation of the four economic-demographic variables was undertaken GDP, whether logged or not, correlated highly with trial output (whether logged or not). Other variables did not (Table [2](#T2){ref-type="table"}). This suggests that trial productivity may neither be a function of national burden of ill people, nor of individual prosperity, and not of technological development. Trial productivity seems more linked with the affluence of the country, irrespective of population, or technological development.

Every country that had not produced any randomised trials relevant to schizophrenia had a current GDP that predicted a study output of zero. The two exceptions (Indonesia and Iraq) had larger GDPs, but interpolation of which into the plot still predicted a study output compatible with zero (see 95% CIs). Every nation that can afford it, and many that cannot, undertake schizophrenia trials.

Table [3](#T3){ref-type="table"}, highlights countries with what may be strong traditions of undertaking and disseminating trials, well beyond that predicted by GDP. On the other hand, the plot suggests that Japan, France, Italy, China and Germany are conducting only between 10--50% of trials predicted by their high GDPs. One reason for these poor results may be that those compiling the Cochrane Schizophrenia Group\'s database are not identifying relevant trials from non-Anglophone sources. These figures would suggest that those seeking as yet unidentified studies should focus efforts on these countries, where searching is likely to be fruitful. Investing effort in finding studies from Thailand, however, where only an additional six studies are predicted to have not yet been identified, may be considerable effort for little reward. Certainly, researchers in Japan are acutely aware of the problem of disseminating their work \[[@B7]\] and have recently created accessible registers to combat this \[[@B8]\]. The under-representation of schizophrenia trials from certain countries could also mean that the studies do not exist and that the tradition of evaluation of care for this client group is not strong in these states.

Twenty-five countries have a GDP that predicts no schizophrenia trial activity yet some is apparent. Table [4](#T4){ref-type="table"} shows those states where more than ten studies have been identified. Israel is out ahead, but with the Czech Republic, where GDP may be a more accurate representation of the state\'s affluence, a close second.

Conclusions
===========

In summary, this hypothesis-generating study finds close correlation between current GDP figures and a country\'s production of schizophrenia trials. It suggests that some states have been remarkably generous in their commitment to evaluation of care of this group of people. For other wealthy countries, however, there is a suggestion that either substantial numbers of randomised trials remain unidentified, or that there is no great interest in randomised trials relevant to people with schizophrenia
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